In this webinar, we’ll explore the challenges that have historically hindered progress in neurotherapeutics and showcase AxoSim’s suite of advanced neuro platforms designed to tackle these issues head-on.
What You’ll Learn:
- An overview of AxoSim’s three neuro platforms, including their unique hallmarks and use-cases for safety and efficacy testing.
- A deep dive into AxoSim’s functional brain organoid platform, featuring consistent spontaneous network activity, a hallmark that enables robust predictive capabilities.
- Insights into the development of a predictive neurotoxicity assay aimed at reducing failures caused by CNS toxicity and seizure liability.
- A case study demonstrating the platform’s application in Rett Syndrome drug discovery, highlighting how AxoSim’s human 3D organoid model delivers critical insights into safety and efficacy.
Speaker
Andrew LaCroix, PhD
Andrew LaCroix is a Lead Scientist at AxoSim specializing in the development of iPSC-derived brain organoid models and their applications to preclinical safety and efficacy testing. Specifically, he has focused on predictive neurotoxicity assays and human-first drug discovery to reduce clinical failure rates and improve patient outcomes.